Amendment to Schedule 13D Filing for Evoke Pharma Inc.

This filing is an amendment to a previously filed Schedule 13D, concerning the Common Stock of Evoke Pharma, Inc. The amendment details the completion of the acquisition of Evoke Pharma, Inc. by Parent, through a merger that became effective on December 17, 2025. As a result of the merger, all outstanding shares of common stock, including those beneficially owned by Nantahala Capital Management, LLC and its principals (Wilmot B. Harkey and Daniel Mack), were converted into the right to receive $11.00 per share in cash. Warrants held by the reporting persons were also cancelled and exchanged for a cash payment. Consequently, the reporting persons have ceased to beneficially own any shares of Evoke Pharma, Inc. The filing also notes the delisting of the shares and termination of their registration under the Exchange Act.